The use of anticoagulation during the periprocedure period of atrial fibrillation ablation

Current Opinion in Cardiology

Volumn 27, Issue 1, 2012, Pages 55-61

  Verma, Atul ^a   Tsang, Bernice ^a  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

atrial fibrillation; catheter ablation; dabigatran; factor Xa inhibitors; heparin; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; THROMBOEMBOLISM;

EID: 83055196708     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834dc34d     Document Type: Article

References (60)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354. (Pubitemid 44252297)
2. Verma A, Macle L, Cox J, Skanes AC. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol 2011; 27:60-66.
3. Verma A. Atrial-fibrillation ablation should be considered first-line therapy for some patients. Curr Opin Cardiol 2008; 23:1-8. (Pubitemid 351339789)
4. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3:32-38.
5. Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA). ClinicalTrials.gov identifier: NCT00911508. http://clinicaltrials. gov/ct2/show/NCT00911508. [Accessed 31 July 2011]
6. Institute for Clinical and Economic Review. Final Report of CEPAC Public Meeting on Treatment for Atrial Fibrillation July 26, 2011. http://www. icer-review.org/index.php/Announcements/cepacafibfinal.html. [Accessed 3 August 2011]
7. Baman TS, Jongnarangsin K, Chugh A, et al. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22:626-631.
8. Scherr D, Sharma K, Dalal D, et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20:1357-1363.
9. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010; 55:735-743.
10. Wazni OM, Rossillo A, Marrouche NF, et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol 2005; 16:576-581. (Pubitemid 40807645)
11. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121:2550-2556.
12. Scherr D, Dalal D, Chilukuri K, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20:379-384.
13. Dagres N, Hindricks G, Kottkamp H, et al. Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol 2009; 20:1014-1019.
14. Callahan TDt, Di Biase L, Horton R, et al. Catheter ablation of atrial fibrillation. Cardiol Clin 2009; 27:163-178, x.
15. Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009; 6:1425-1429.
16. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116:2531-2534. (Pubitemid 350179218)
17. Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008; 19:627-631. (Pubitemid 351832292)
18. Bertaglia E, Zoppo F, Tondo C, et al. Early complications of pulmonary vein catheter ablation for atrial fibrillation: a multicenter prospective registry on procedural safety. Heart Rhythm 2007; 4:1265-1271. (Pubitemid 47495727)
19. He H, Kang J, Tao H, et al. Conventional oral anticoagulation may not replace prior transesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation. J Interv Card Electrophysiol 2009; 24:19-26.
20. Wallace TW, Atwater BD, Daubert JP, et al. Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. J Cardiovasc Electrophysiol 2010; 21:849-852.
21. Fruhauf M, Eitel C, Bollmann A, et al. Should transesophageal echocardiography be done in all patients who underwent catheter ablation of atrial fibrillation? A case report and review of the literature. Clin Res Cardiol 2010; 99:125-128.
22. Knight BP. Transesophageal echocardiography before atrial fibrillation ablation: looking before cooking. J Am Coll Cardiol 2009; 54:2040-2042.
23. Ramaraj R. Transesophageal echocardiography for the prevention of embolic complications after catheter ablation for atrial fibrillation using validated guidelines. J Cardiovasc Electrophysiol 2009; 20:E74; author reply E75.
24. Cappato R. Searching for left atrial thrombi prior to catheter ablation of atrial fibrillation: are there patients who can safely avoid preablation transesophageal echocardiography? J Cardiovasc Electrophysiol 2009; 20:385-387.
25. Calvo N, Mont L, Vidal B, et al. Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory? Europace 2011; 13:486-491.
26. Yamashita E, Takamatsu H, Tada H, et al. Transesophageal echocardiography for thrombus screening prior to left atrial catheter ablation. Circ J 2010; 74:1081-1086.
27. McCready JW, Nunn L, Lambiase PD, et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is preprocedural transoesophageal echocardiography mandatory? Europace 2010; 12:927-932.
28. Michael KA, Redfearn DP, Baranchuk A, et al. Transesophageal echocardiography for the prevention of embolic complications after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20:1217-1222.
29. Gula LJ, Massel D, Redfearn DP, et al. Impact of routine transoesophageal echocardiography on safety, outcomes, and cost of pulmonary vein ablation: inferences drawn from a decision analysis model. Europace 2010; 12:1550-1557.
30. Chilukuri K, Mayer SA, Scherr D, et al. Transoesophageal echocardiography predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. Europace 2010; 12:1543-1549.
31. Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009; 54:2032-2039.
32. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816-861. (Pubitemid 46850611)
33. Hsu LF, Jais P, HociniM, et al. Incidence and prevention of cardiac tamponade complicating ablation for atrial fibrillation. Pacing Clin Electrophysiol 2005; 28 (Suppl 1):S106-S109.
34. Latchamsetty R, Gautam S, Bhakta D, et al. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 2011; 8:805-808.
35. Di Biase L, Burkhardt JD, Lakkireddy DJ, et al. Catheter ablation of atrial fibrillation under therapeutic coumadin: prevalence of pericardial effusion comparing paroxysmal and nonparoxysmal atrial fibrillation EUROPACE 2011; Abstract 19 Europace (2011) 13 (Suppl 3): NP. doi: 10.1093/europace/ eur211. 2011.
36. Dhruvakumar S, Gerstenfeld EP. Complications associated with catheter ablation of atrial fibrillation. Minerva Cardioangiol 2007; 55:353-368. (Pubitemid 47066399)
37. Cauchemez B, Extramiana F, Cauchemez S, et al. High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium. J Cardiovasc Electrophysiol 2004; 15:276-283. (Pubitemid 38429439)
38. Essebag V, Birnie D, Guerra P, et al. Anticoagulation management pre and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol 2010; 26:112D-1112D.
39. Natale A, Raviele A, Al-Ahmad A, et al. Venice Chart International Consensus document on ventricular tachycardia/ventricular fibrillation ablation. J Cardiovasc Electrophysiol 2010; 21:339-379.
40. Prudente LA, Moorman JR, Lake D, et al. Femoral vascular complications following catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 2009; 26:59-64.
41. Shea JB. Anticoagulation practice in cardiac electrophysiology. Heart Rhythm 2006; 3:372-374. (Pubitemid 43264420)
42. Mortada ME, Chandrasekaran K, Nangia V, et al. Periprocedural anticoagulation for atrial fibrillation ablation. J Cardiovasc Electrophysiol 2008; 19:362-366. (Pubitemid 351457561)
43. Bunch TJ, Crandall BG, Weiss JP, et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2009; 20:988-993.
44. Kwak JJ, Pak HN, Jang JK, et al. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21:620-625.
45. Santangeli P, Di Biase L, Sanchez JE, et al. Atrial fibrillation ablation without interruption of anticoagulation. Cardiol Res Pract 2011; 837-841.
46. Gopinath D, Lewis WR, Biase LD, Natale A. Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. J Cardiovasc Electrophysiol 2011; 22:236-239.
47. Schmidt M, Segerson NM, Marschang H, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2009; 32:995-999.
48. Gautam S, John RM, Stevenson WG, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22:248-254.
49. Birnie D. Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL). In ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US). 2000. http://www. clinicaltrials.gov/ ct2/show/NCT00800137. NLM Identifier: NCT00800137. [Accessed 3 July 2011]
50. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817.
51. Patel MR. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 2010; 122:2217-12217.
52. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
53. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med. 2011; 365:981-992.
54. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340-347, e341.
55. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48:1-22.
56. Pradaxa prescribing information. March 2011. Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BIWebAccess/View- Servlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/ Pradaxa/Pradaxa.pdf. [Accessed 11 August 2011]
57. Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010; 29:182-191.
58. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S-198S. (Pubitemid 351892967)
59. USP DI1 Volume I: Drug Information for the Healthcare Professional [Internet database]. Greenwood Village, Colo: Thomson Micromedex.
60. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114:759-765. (Pubitemid 44268226)